David Wells Sells Shares of Hims & Hers Health

David Wells, an insider at Hims & Hers Health, Inc. (NYSE:HIMS), sold 3,656 shares on June 11, 2026. The transaction was not part of a pre-planned trading arrangement. The stock is currently trading around $26.82.

Other Institutional Activity in Hims & Hers Health

Several major funds have recently adjusted their holdings in Hims & Hers Health. BlackRock, Inc. reduced its stake by 236,346 shares, leaving it with 26,337,158 shares valued at roughly $546.8 million. In contrast, Morgan Stanley increased its position significantly, adding 4,959,856 shares to reach a total of 8,889,088 shares, valued at approximately $184.5 million. Additionally, State Street Corp added 154,498 shares, bringing its total to 7,460,023 shares worth about $154.9 million.

Hims & Hers Health Stock Snapshot

Shares of NYSE:HIMS are trading near $26.82. Hims & Hers Health has a market cap of approximately $6.21 billion and a forward P/E ratio of 30.13. The stock has a 52-week low of $13.74 and a high of $70.43. It also has a 50-day moving average of $25.63 and a 200-day moving average of $33.57. The company has a beta of 2.398, indicating higher volatility compared to the market.

Insider Buying and Selling at Hims & Hers Health, Inc.

In addition to David Wells' recent sale, other insiders have been active. Christopher Payne sold 10,687 shares on June 15, 2026, and Anja Manuel sold 10,040 shares on the same day. Patrick Harrison Carroll, the Chief Medical Officer, also sold 435 shares on June 15, 2026. These transactions were not part of any pre-arranged trading plans.

Analysts Set New Price Targets

On May 26, 2026, B of A Securities maintained a "hold" rating on Hims & Hers Health with a $25.00 price target. Similarly, Truist Securities maintained its "hold" rating with a $23.00 target on May 22, 2026. JP Morgan initiated coverage with a "buy" rating and a $35.00 target on April 24, 2026.

About Hims & Hers Health

Hims & Hers Health, Inc. is a healthcare company based in San Francisco, California. It operates a platform connecting consumers with licensed healthcare professionals across the U.S. and several international markets. The company offers a variety of health and wellness products, including prescription and non-prescription items, as well as personalized services. With a focus on general wellness, skincare, sexual health, and more, Hims & Hers aims to provide accessible healthcare solutions. The company is led by CEO Andrew Dudum and employs over 2,400 people.

Bottom Line

David Wells' recent sale of shares in Hims & Hers Health, Inc. is part of ongoing insider activity at the company. Investors track these moves to gauge insider sentiment. It's important to remember that such filings are reported after the fact and may not reflect the insider's current position.